Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 20.4% in August

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,290,000 shares, a decline of 20.4% from the August 15th total of 1,620,000 shares. Based on an average daily trading volume, of 531,800 shares, the short-interest ratio is presently 2.4 days.

Wall Street Analysts Forecast Growth

BCLI has been the subject of several analyst reports. Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Thursday, July 11th. StockNews.com initiated coverage on Brainstorm Cell Therapeutics in a research note on Sunday. They set a “hold” rating for the company.

Brainstorm Cell Therapeutics Stock Up 2.9 %

Shares of BCLI stock traded up $0.01 on Tuesday, reaching $0.27. The company had a trading volume of 19,562 shares, compared to its average volume of 740,406. The stock has a market capitalization of $19.19 million, a PE ratio of -0.83 and a beta of 0.35. The business’s 50-day moving average is $0.33 and its 200 day moving average is $0.42. Brainstorm Cell Therapeutics has a one year low of $0.13 and a one year high of $1.08.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the company earned ($0.27) EPS. On average, sell-side analysts forecast that Brainstorm Cell Therapeutics will post -0.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.